Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial
Crossref DOI link:
Published Online: 2017-02-10
Published Print: 2017-12
Update policy: https://doi.org/10.1007/SPRINGER_CROSSMARK_POLICY
Arnold, Douglas L.
Calabresi, Peter A.
Kieseier, Bernd C.
Funding for this research was provided by: